Integrated Filing — IndAS



General information about company

Scrip Code 530199
NSE Symbol THEMISMED
MSEI Symbol NA
ISIN INE083B01024
Name of company THEMIS MEDICARE LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2025
Date of end of financial year 31-03-2026
Date of board meeting when results were approved 13-11-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 04-11-2025
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Second quarter
Nature of report standalone or consolidated Consolidated
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Single segment
Description of single segment Pharmaceutical
Start date and time of board meeting 13-11-2025   12:00:00
End date and time of board meeting 13-11-2025   13:00:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2025 01-04-2025
B Date of end of reporting period 30-09-2025 30-09-2025
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Consolidated Consolidated
1 Income
Revenue from operations 7,799.41 17,557.18
Other income 323.64 441.23
Total income 8,123.05 17,998.41
2 Expenses
(a) Cost of materials consumed 1,610.83 2,853.82
(b) Purchases of stock-in-trade 1,822.81 3,990.39
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (1,019.09) 810.18
(d) Employee benefit expense 2,493.10 4,978.01
(e) Finance costs 276.49 523.51
(f) Depreciation, depletion and amortisation expense 257.45 512.73
(f) Other Expenses
1 Other Expenses 3,200.52 6,241.71
Total other expenses 3,200.52 6,241.71
Total expenses 8,642.11 19,910.35
3 Total profit before exceptional items and tax (519.06) (1,911.94)
4 Exceptional items 0.00 0.00
5 Total profit before tax (519.06) (1,911.94)
6 Tax expense
7 Current tax 0.00 0.00
8 Deferred tax 16.49 32.01
9 Total tax expenses 16.49 32.01
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations (535.55) (1,943.95)
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 173.99 160.42
16 Total profit (loss) for period (361.56) (1,783.53)
17 Other comprehensive income net of taxes (7.41) (10.21)
18 Total Comprehensive Income for the period (368.97) (1,793.74)
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent (361.564) (1,783.516)
Total profit or loss, attributable to non-controlling interests 0.00 (0.01)
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent (368.975) (1,793.726)
Total comprehensive income for the period attributable to owners of parent non-controlling interests 0.00 (0.01)
21 Details of equity share capital
Paid-up equity share capital 920.40 920.40
Face value of equity share capital 10 10
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations -0.39 -1.94
Diluted earnings (loss) per share from continuing operations -0.39 -1.93
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations -0.39 -1.94
Diluted earnings (loss) per share from continuing and discontinued operations -0.39 -1.93
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) 1) The above Unaudited Financial Results were reviewed by the Audit Committee and have been considered and approved by the Board of Directors at its respective meeting held on November 13, 2025. 2) The above financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) as prescribed under section 133 of the Companies Act , 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and the Companies (Indian Accounting Standards) Rules, 2016. 3) The Company operates in a single Business segment i.e Pharmaceuticals and hence does not have any reportable segments as per Indian Accounting Standard (Ind AS) 108 - Operating Segments. 4)The Board of Directors of the Company, at its meeting held on November 18, 2024, had approved the Scheme of Amalgamation (Scheme) between Gujarat Themis Biosyn Limited (GTBL) and the Company and their respective shareholders under sections 230 to 232 and other applicable provisions of the Companies Act, 2013, subject to receipt of necessary regulatory and other approvals. However, the Board of Directors of GTBL, at its meeting held on June 13, 2025 after evaluating new developments in the market decided to focus on its core business of fermentation-based pharmaceutical intermediates and active pharmaceutical ingredients and decided to revisit all its strategic options. Consequently, the GTBL Board reconsidered its earlier decision of merger and resolved not to proceed with the proposed merger. Accordingly, the GTBL Board has approved the withdrawal of the Scheme as permitted under clause 21 of the Scheme. In alignment with this decision, the Board of Directors of the Company in their meeting held on June 13, 2025 has resolved to withdraw the said Scheme of Amalgamation. Pursuant to this, the Company shall continue to focus on its core domestic formulations business with the objective of achieving long-term sustainable growth. 5) The company has received an approval for struck off M/s. Carpo Medicals Limited (UK), a wholly owned subsidiary company by issue of a gazette notification on 01st April 2025 for dissolution w.e.f 14th April 2025 by the Company House, UK. Accordingly, the company has provided for Investment Rs. 0.76 lacs and Receivable and advances amounting to Rs. 128.63 Lacs in the Financial Statement as the Company is in the process of obtaining approval from the Reserve Bank of India (RBI) under the Foreign Exchange Management Act (FEMA), 1999, for writing off the said investments. The company has disclosed the Investments, receivables and advances provided for, as an exceptional item in the Statement of Profit and Loss in accordance with Ind AS 1 and applicable accounting principles. Subject to approvals from RBI for striking off the said foreign subsidiary, as per the provisions of the FEMA and applicable ODI regulations, the amounts will be written-off. 6) Figures for the corresponding previous year/period have been regrouped/rearranged, wherever necessary, to make them comparable.



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2025
Date of end of reporting period 30-09-2025
Whether results are audited or unaudited Unaudited
Nature of report standalone or consolidated Consolidated
Assets
1 Non-current assets
Property, plant and equipment 16,868.84
Capital work-in-progress 338.52
Investment property 0.00
Goodwill 0.00
Other intangible assets 22.44
Intangible assets under development 0.00
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 9,605.89
Non-current financial assets
Non-current investments 34.60
Trade receivables, non-current 0.00
Loans, non-current 0.00
Other non-current financial assets 122.54
Total non-current financial assets 157.14
Deferred tax assets (net) 0.00
Other non-current assets 1,356.21
Total non-current assets 28,349.04
2 Current assets
Inventories 7,644.69
Current financial asset
Current investments 0.00
Trade receivables, current 17,342.78
Cash and cash equivalents 813.35
Bank balance other than cash and cash equivalents 461.18
Loans, current 0.00
Other current financial assets 621.35
Total current financial assets 19,238.66
Current tax assets (net) 0.00
Other current assets 3,017.14
Total current assets 29,900.49
3 Non-current assets classified as held for sale 0.00
4 Regulatory deferral account debit balances and related deferred tax Assets 0.00
Total assets 58,249.53
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 920.40
Other equity 37,080.43
Total equity attributable to owners of parent 38,000.83
Non controlling interest (0.15)
Total equity 38,000.68
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 1,760.60
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities
Total non-current financial liabilities 1,760.60
Provisions, non-current 186.50
Deferred tax liabilities (net) 909.88
Deferred government grants, Non-current 0.00
Other non-current liabilities 0.00
Total non-current liabilities 2,856.98
Current liabilities
Current financial liabilities
Borrowings, current 7,795.76
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 221.12
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 4,453.97
Total Trade payable 4,675.09
Other current financial liabilities 3,329.46
Total current financial liabilities 15,800.31
Other current liabilities 713.14
Provisions, current 293.42
Current tax liabilities (Net) 585.00
Deferred government grants, Current 0.00
Total current liabilities 17,391.87
3 Liabilities directly associated with assets in disposal group classified as held for sale 0.00
4 Regulatory deferral account credit balances and related deferred tax liability 0.00
Total liabilities 20,248.85
Total equity and liabilites 58,249.53
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-07-2025 01-04-2025
Date of end of reporting period 30-09-2025 30-09-2025
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Consolidated Consolidated
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2025 01-04-2025
B Date of end of reporting period 30-09-2025 30-09-2025
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Consolidated Consolidated
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Items that will not be reclassified to profit and loss -1032000 -2065000
2 Share of Other Comprehensive Income of Associates and Joint Ventures accounted using equity method 30000 59000
Total Amount of items that will not be reclassified to profit and loss (10.02) (20.06)
2 Income tax relating to items that will not be reclassified to profit or loss (2.60) (5.20)
3 Amount of items that will be reclassified to profit and loss
1 Items that will be reclassified to profit & loss 1000 465000
Total Amount of items that will be reclassified to profit and loss 0.01 4.65
4 Income tax relating to items that will be reclassified to profit or loss 0.00 0.00
5 Total Other comprehensive income (7.41) (10.21)



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2025
B Date of end of reporting period 30-09-2025
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Consolidated
Statement of cash flows
Cash flows from used in operating activities
Profit before tax (1,911.94)
Adjustments for reconcile profit (loss)
Adjustments for finance costs 0.00
Adjustments for decrease (increase) in inventories 786.76
Adjustments for decrease (increase) in trade receivables, current 367.46
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets (677.07)
Adjustments for decrease (increase) in other non-current assets 0.00
Adjustments for other financial assets, non-current 0.00
Adjustments for other financial assets, current (4.39)
Adjustments for other bank balances 166.56
Adjustments for increase (decrease) in trade payables, current (468.66)
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities 600.18
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 512.73
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current 92.41
Adjustments for provisions, non-current 0.00
Adjustments for other financial liabilities, current 176.73
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains 0.00
Adjustments for dividend income 0.00
Adjustments for interest income 0.00
Adjustments for share-based payments 0.00
Adjustments for fair value losses (gains) (2.78)
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow 0.00
Other adjustments to reconcile profit (loss) 0.00
Other adjustments for non-cash items (0.71)
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) 1,549.22
Net cash flows from (used in) operations (362.72)
Dividends received (187.21)
Interest paid (423.26)
Interest received 0.00
Income taxes paid (refund) 21.73
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities (148.40)
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 0.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 0.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 0.00
Purchase of property, plant and equipment 255.45
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 169.33
Interest received 17.88
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) investing activities (68.24)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 0.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 1,358.09
Repayments of borrowings 100.58
Payments of lease liabilities 0.00
Dividends paid 460.20
Interest paid 423.26
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities 374.05
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 157.41
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0.00
Net increase (decrease) in cash and cash equivalents 157.41
Cash and cash equivalents cash flow statement at beginning of period 655.94
Cash and cash equivalents cash flow statement at end of period 813.35





Details of Impact of Audit Qualification

Amount in (Lakhs)

Whether results are audited or unaudited Unaudited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 KRISHAAN AND CO Yes 31-07-2027